2076975 2077203
최종편집 2024-06-18 17:24 (화)
Top pharmaceutical companies’ cost burden is reduced, and the SG&A ratio increased
상태바
Top pharmaceutical companies’ cost burden is reduced, and the SG&A ratio increased
  • Hyeokgi Lee, Newsmp
  • 승인 2021.11.08 18:03
  • 댓글 0
이 기사를 공유합니다

Average COGS ratio of 6 companies is 59.3%... a 3.0% decrease YoY

           SG&A ratio also decreased by 1.2%p… only Hanmi pharmaceutical dropped

In the third quarter, the cost of sales burden for top pharmaceutical companies decreased slightly.

The average cost of goods sold (COGS) ratio of six top pharmaceutical companies, including GC Pharma, Yuhan Corporation, Chong Kun Dang Pharmaceutical, Hanmi Pharmaceutical, Daewoong Pharmaceutical, and Dong-A ST, fell 3.0% YoY to 59.3% in 3Q, according to a recently released report.

Daewoong Pharmaceutical’s COGS ratio plunged 6.25%p from 61.1% to 54.9%, GC Pharma fell 5.7%p from 65.9% to 60.2%, Hanmi Pharmaceutical 5.5%p from 52.6% to 47.1%, and Dong-A ST 5.5%p from 54.2% to 48.7%.

During the same period, Yuhan Corporation’s COGS ratio rose 2.3%p from 68.3% to 70.6%, and Chong Kun Dang Pharmaceutical also slightly expanded from 62.2% to 62.3%.

The average selling, general & administrative expenses (SG&A) of the six companies also dropped 1.2%p from 31.4% to 30.2%, the lowest since the COVID-19 pandemic began.

Only Hanmi Pharmaceutical succeeded in lowering the SG&A ratio.

The SG&A ratio of GC Pharma and Chong Kun Dang Pharmaceutical rose 2.6%p YoY, Dong-A ST 1.3%p, and Yuhan Corporation 1.0%p, while Daewoong Pharmaceutical remained at the same level.

Nevertheless, as Hanmi Pharmaceutical’s SG&A ratio decreased by 18.8%p from 59.5% to 40.7%, or by KRW 35.2 billion from KRW 158.7 billion to KRW 123.5 billion, the average SG&A ratio of six companies also declined significantly.


댓글삭제
삭제한 댓글은 다시 복구할 수 없습니다.
그래도 삭제하시겠습니까?
댓글 0
댓글쓰기
계정을 선택하시면 로그인·계정인증을 통해
댓글을 남기실 수 있습니다.